Boehringer Ingelheim International is a global pharmaceutical company engaged in human pharmaceuticals, animal health, and biopharmaceuticals businesses. It focuses on researching medicines and offering therapies for diseases for which satisfactory treatment options are currently unavailable and provides the entire value chain, starting from research and development through the production and commercialization of its products. The company provides treatments for cardiovascular and metabolic diseases, oncology, diseases of the central nervous system, infectious diseases, as well as veterinary vaccines and medicines, and a variety of biopharmaceuticals. C.H. Boehringer Sohn is the parent company of Boehringer Ingelheim International.

Employee Rating

4.1More
TypeSubsidiary
HQIngelheim am Rhein, DE
Founded1885
Websiteboehringer-ingelheim.com
Cybersecurity ratingBMore
Boehringer Ingelheim was founded in 1885 and is headquartered in Ingelheim am Rhein, DE
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Boehringer Ingelheim

Hubertus von Baumbach

Hubertus von Baumbach

Chairman of the Board of Managing Directors
Carinne Brouillon

Carinne Brouillon

Member of the Board of Managing Directors, Human Pharma Business Unit
Michel Pairet

Michel Pairet

Member of the Board of Managing Directors, Innovation Unit
Jean Scheftsik de Szolnok

Jean Scheftsik de Szolnok

Member of the Board of Managing Directors, Animal Health Business Unit
Michael Schmelmer

Michael Schmelmer

Member of the Board of Managing Directors, Finance & Group Functions
Show more

Boehringer Ingelheim Office Locations

Boehringer Ingelheim has offices in Ingelheim am Rhein, Duluth, Ridgefield, Algiers and in 69 other locations
Ingelheim am Rhein, DE (HQ)
Binger Str. 173
Algiers, DZ
Coopérative El Yasmine, 29 route du stade, Ouled Fayet
Munro, AR
piso 2, EAA, Cazadores de Coquimbo 2841
Macquarie Park, AU
Level 1/78 Waterloo Rd
Vienna, AT
Dr.-Boehringer-Gasse 5-11
Minsk, BY
V. Khoruzhej street 22, office 1402
Show all (74)

Boehringer Ingelheim Financials and Metrics

Summary Metrics

Founding Date

1885

Boehringer Ingelheim Revenue

Embed Graph
View revenue for all periods
Boehringer Ingelheim's revenue was reported to be €21.27 b in FY, 2019 which is a 8.4% increase from the previous period.
EURFY, 2017FY, 2018FY, 2019

Revenue

21.2b19.6b21.3b

Revenue growth, %

15%(7%)8%

Cost of goods sold

7.6b7.3b7.3b

Gross profit

13.6b12.3b14.0b
EURFY, 2017FY, 2018FY, 2019

Cash

3.1b4.3b2.2b

Accounts Receivable

3.1b3.5b4.2b

Prepaid Expenses

334.0m377.0m313.0m

Inventories

3.1b3.3b3.6b
EURFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

1.8b(229.0m)2.1b2.7b

Depreciation and Amortization

620.0m963.0m1.1b1.2b

Inventories

(249.0m)305.0m(229.0m)(274.0m)

Accounts Payable

151.0m(60.0m)8.0m9.0m
Show all financial metrics

Boehringer Ingelheim Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Active Clinical Studies

500400400

Manufacturing Facilities (Human Pharmaceuticals)

191620

New Products

200300200

Projects in Pipeline

90
Show all operating metrics

Boehringer Ingelheim Acquisitions / Subsidiaries

Company NameDateDeal Size
NBE-TherapeuticsDecember 10, 2020€1.18 b
Labor Dr. Merk & KollegenDecember 09, 2020
Global Stem cell TechnologyJuly 27, 2020
Northern BiologicsMay 14, 2020
Amal TherapeuticsJuly 15, 2019€325 m
ICD TherapeuticsMarch 29, 2019
ViraTherapeuticsSeptember 13, 2018$245 m
Funxional TherapeuticsJuly 23, 2012
Actimis PharmaceuticalsJune 17, 2008$515 m
International Diagnostic TechnologyJanuary 01, 1978
Show more

Boehringer Ingelheim Revenue Breakdown

Embed Graph

Boehringer Ingelheim revenue breakdown by business segment: 21.2% from Animal Health, 73.5% from Human Pharmaceuticals and 5.3% from Other

Boehringer Ingelheim revenue breakdown by geographic segment: 23.6% from Asia/Australia/Africa, 29.9% from Europe and 46.5% from Americas

Show all human capital metrics

Boehringer Ingelheim Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Boehringer Ingelheim Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Boehringer Ingelheim Online and Social Media Presence

Embed Graph

Boehringer Ingelheim Company Culture

  • Overall Culture

    C

    66/100

  • CEO Rating

    C+

    68/100

  • Compensation

    A-

    76/100

Learn more on Comparably

Boehringer Ingelheim News and Updates

Greater Good Charities, with Boehringer Ingelheim Animal Health and The Animal Rescue Site Celebrate Anniversary of Good Flights Program and Successfully Transport Nearly 500 Asymptomatic Heartworm-Positive Shelter Dogs to Adoptive Homes

More than 1,600 at-risk shelter dogs in Louisiana transported to the East Coast, marking first year of “Save a Heart” Initiative More than 1,600 at-risk shelter dogs in Louisiana transported to the East Coast, marking first year of “Save a Heart” Initiative

Oxford BioTherapeutics Grants Third Exclusive License to Boehringer Ingelheim for Development and Commercialization of Antibody Products to a Novel Oncology Target

OXFORD, England and SAN JOSE, Calif., April 13, 2022 /PRNewswire/ -- Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced that Boehringer Ingelheim has exercised its option to...

Boehringer Ingelheim Selects Veeva Development Cloud Worldwide to Bring Innovative Therapies to Patients Faster

With Veeva Development Cloud, Boehringer Ingelheim aims to establish a connected technology landscape for agile collaboration that can accelerate the development of novel medicines Transformation focuses on reducing complexity and developing an innovative, digital culture to better...

Global Biologics Contract Development and Manufacturing Organizations Report 2022 Featuring Lonza, Samsung, Boehringer Ingelheim BioXcellenceT, Thermo Fisher Scientific, WuXi Biologics, Catalent, AGC

Dublin, March 25, 2022 (GLOBE NEWSWIRE) -- The "Global Biologics Contract Development and Manufacturing Organization Profiles and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Global Vascular Endothelial Growth Factor Inhibitors Pipeline 2022, Featuring Profiles of Adverum Biotechnologies, Sandoz, Boehringer Ingelheim, Allarity Therapeutics and Kodiak Sciences

Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Vascular Endothel…

Global Anticoagulant Reversal Drugs Market special industry drivers, different growth opportunities Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc says Calibre Research

DALLAS, Feb. 15, 2022 /PRNewswire/ -- A newly published report entitled as Global Anticoagulant Reversal Drugs Market research is accountable to illustrate a comprehensive data on several emerging trends, special industry drivers, different growth opportunities as well as constraints that...
Show more

Boehringer Ingelheim Frequently Asked Questions

  • When was Boehringer Ingelheim founded?

    Boehringer Ingelheim was founded in 1885.

  • Who are Boehringer Ingelheim key executives?

    Boehringer Ingelheim's key executives are Hubertus von Baumbach, Carinne Brouillon and Michel Pairet.

  • How many employees does Boehringer Ingelheim have?

    Boehringer Ingelheim has 52,391 employees.

  • What is Boehringer Ingelheim revenue?

    Latest Boehringer Ingelheim annual revenue is €21.3 b.

  • What is Boehringer Ingelheim revenue per employee?

    Latest Boehringer Ingelheim revenue per employee is €406 k.

  • Who are Boehringer Ingelheim competitors?

    Competitors of Boehringer Ingelheim include Daiichi Sankyo, Pfizer and Zoetis.

  • Where is Boehringer Ingelheim headquarters?

    Boehringer Ingelheim headquarters is located at Binger Str. 173, Ingelheim am Rhein.

  • Where are Boehringer Ingelheim offices?

    Boehringer Ingelheim has offices in Ingelheim am Rhein, Duluth, Ridgefield, Algiers and in 69 other locations.

  • How many offices does Boehringer Ingelheim have?

    Boehringer Ingelheim has 74 offices.